- Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era
-
Jang ES, Kim YS, Kim KA, Lee YJ, Chung WJ, Kim IH, Lee BS, Jeong SH
- KMID: 2412235
- Gut Liver.
- 2017 Jul;11(4):543-550.
- doi: 10.5009/gnl16530
BACKGROUND/AIMS: To evaluate the era of direct acting antivirals (DAAs), we must understand the treatment patterns and outcomes of interferon-based therapy for hepatitis C virus (HCV) infection. We aimed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B
-
Sohn W, Cho JY, Kim JH, Lee JI, Kim HJ, Woo MA, Jung SH, Paik YH
- KMID: 2413121
- Clin Mol Hepatol.
- 2017 Jun;23(2):170-178.
- doi: 10.3350/cmh.2016.0086
BACKGROUND/AIMS: This study aimed to develop and validate a risk prediction model for the development of hepatocellular carcinoma (HCC) in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B
-
Seo HY, Lee HA, Ko SY, Wang JH, Kim JH, Choe WH, Kwon SY
- KMID: 2413119
- Clin Mol Hepatol.
- 2017 Jun;23(2):154-159.
- doi: 10.3350/cmh.2016.0067
BACKGROUND/AIMS: Little is known about the effect of early flares on response during first-line tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B (CHB). The aim of this study was... -
- CITED
-
- Close
- SHARE
-
- Close
- Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
-
Kim DH, Choi JW, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Shin SY, Lee CK
- KMID: 2419112
- Yonsei Med J.
- 2017 May;58(3):552-556.
- doi: 10.3349/ymj.2017.58.3.552
PURPOSE: This study examined 2-year outcome of consecutive therapy using entecavir (ETV) followed by telbivudine (LdT) in subjects with undetectable hepatitis B virus (HBV) DNA level and normal alanine aminotransferase... -
- CITED
-
- Close
- SHARE
-
- Close
- Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
-
Toshikuni
- KMID: 2412206
- Gut Liver.
- 2017 May;11(3):335-348.
- doi: 10.5009/gnl15458
Chronic hepatitis C virus (HCV) infection may eventually lead to liver cirrhosis (LC), a condition associated with a high risk of liver failure and hepatocellular carcinoma. Although interferon (IFN)-based therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Antiviral Resistance in Chronic Hepatitis B
-
Lim YS
- KMID: 2412184
- Gut Liver.
- 2017 Mar;11(2):189-195.
- doi: 10.5009/gnl15562
The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint... -
- CITED
-
- Close
- SHARE
-
- Close
- Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
-
Seo KI, Yun BC, Li WJ, Lee SU, Han BH, Park ET
- KMID: 2412117
- Clin Mol Hepatol.
- 2017 Mar;23(1):74-79.
- doi: 10.3350/cmh.2016.0052
BACKGROUND/AIMS: Interferon-based treatment is not appropriate for a large number of patients with chronic hepatitis C for various medical and social reasons. Newly developed directly acting antivirals (DAAs) have been... -
- CITED
-
- Close
- SHARE
-
- Close
- Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients
-
Chung GE, Cho EJ, Lee JH, Yoo JJ, Lee M, Cho Y, Lee DH, Kim HY, Yu SJ, Kim YJ, Yoon JH, Zoulim F
- KMID: 2412116
- Clin Mol Hepatol.
- 2017 Mar;23(1):66-73.
- doi: 10.3350/cmh.2016.0060
BACKGROUND/AIMS: A recent study reported that entecavir had inferior efficacy in nucleos(t)ide analogue (NA)-experienced chronic hepatitis B (CHB) patients compared to NA-naïve patients. We sought to compare the efficacy of... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study
-
Cho EY, Yim HJ, Jung YK, Suh SJ, Seo YS, Kim JH, Kim HS, Lee SH, Ahn SH, Lee JI, Jeong SH, Kim JW, Lee JW, Kim IH, Kim HS, Park SJ, Lee JM, Hwang SG
- KMID: 2412164
- Gut Liver.
- 2017 Jan;11(1):129-135.
- doi: 10.5009/gnl15597
BACKGROUND/AIMS: Data are lacking regarding the management of chronic hepatitis B (CHB) with resistance to clevudine (CLV). This study evaluated the efficacy of different rescue therapies for CLV-resistant CHB. METHODS: Patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization
-
Yoo SH, Jang JW, Kwon JH, Jung SM, Jang B, Choi JY
- KMID: 2373150
- Clin Mol Hepatol.
- 2016 Dec;22(4):458-465.
- doi: 10.3350/cmh.2016.0054
BACKGROUND/AIMS: Hepatic damage during transarterial chemoembolization (TACE) is a critical complication in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Apart from its role in preventing HBV reactivation, there... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
-
Lee HW, Park JY, Kim BK, Kim MY, Lee JI, Kim YS, Yoon KT, Han KH, Ahn SH
- KMID: 2373148
- Clin Mol Hepatol.
- 2016 Dec;22(4):443-449.
- doi: 10.3350/cmh.2016.0037
BACKGROUND/AIMS: It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of direct antiviral agent failures
-
Buti M, Esteban R
- KMID: 2373146
- Clin Mol Hepatol.
- 2016 Dec;22(4):432-438.
- doi: 10.3350/cmh.2016.0107
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). Most HCV patients treated with these drugs achieve... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B
-
Shim JJ, Oh IH, Kim SB, Kim JW, Lee CK, Jang JY, Lee JS, Kim BH
- KMID: 2412103
- Gut Liver.
- 2016 Nov;10(6):962-968.
- doi: 10.5009/gnl15426
BACKGROUND/AIMS: The benefit of oral antiviral therapy in preventing hepatocellular carcinoma (HCC) in the general population is not well understood. We used a novel prediction method to estimate the risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma
-
Kim JH, Sinn DH, Kim K, Kim H, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW
- KMID: 2412100
- Gut Liver.
- 2016 Nov;10(6):939-947.
- doi: 10.5009/gnl15527
BACKGROUND/AIMS: Antiviral therapy is a key component in the management of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. However, whether the potent drug entecavir is more effective than a... -
- CITED
-
- Close
- SHARE
-
- Close
- Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy
-
Lee SJ, Cho YK, Na SY, Choi EK, Boo SJ, Jeong SU, Song HJ, Kim HU, Kim BS, Song BC
- KMID: 2373140
- Clin Mol Hepatol.
- 2016 Sep;22(3):390-395.
- doi: 10.3350/cmh.2015.0050
Some recent studies have found regression of liver cirrhosis after antiviral therapy in patients with hepatitis C virus (HCV)-related liver cirrhosis, but there have been no reports of complete regression... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
-
Lee HA, Seo YS, Park SW, Park SJ, Kim TH, Suh SJ, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Byun KS, Um SH
- KMID: 2373139
- Clin Mol Hepatol.
- 2016 Sep;22(3):382-389.
- doi: 10.3350/cmh.2016.0047
BACKGROUND/AIMS: Clear indicators for stopping antiviral therapy in chronic hepatitis B (CHB) patients are not yet available. Since the level of hepatitis B surface antigen (HBsAg) is correlated with covalently... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
-
Kim HJ, Park SK, Yang HJ, Jung YS, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Choi KY
- KMID: 2373135
- Clin Mol Hepatol.
- 2016 Sep;22(3):350-358.
- doi: 10.3350/cmh.2016.0019
BACKGROUND/AIMS: To analyze the effects of preexisting lamivudine (LAM) resistance and applying antiviral treatment (adefovir [ADV] add-on LAM combination treatment) on long-term treatment outcomes, and comparing the clinical outcomes of... -
- CITED
-
- Close
- SHARE
-
- Close
- Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B
-
Lee J, Yoo SH, Sohn W, Kim HW, Choi YS, Won JH, Heo JY, Park SJ, Park YM
- KMID: 2373134
- Clin Mol Hepatol.
- 2016 Sep;22(3):339-349.
- doi: 10.3350/cmh.2016.0021
BACKGROUND/AIMS: This study aimed to clarify the effect of obesity on the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving antiviral treatment. METHODS: This study applied a... -
- CITED
-
- Close
- SHARE
-
- Close
- Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B
-
Wi CI, Kim WR, Gross JB, Stadheim L, Poterucha
- KMID: 2412051
- Gut Liver.
- 2016 Jul;10(4):611-616.
- doi: 10.5009/gnl14256
BACKGROUND/AIMS: Despite the potent suppression of the hepatitis B virus with modern antiviral agents, only a minority of HBeAg-positive patients achieve hepatitis B e antigen seroconversion. We aimed to explore... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
-
Nam HC, Lee HL, Yang H, Song MJ
- KMID: 2373122
- Clin Mol Hepatol.
- 2016 Jun;22(2):259-266.
- doi: 10.3350/cmh.2016.0020
BACKGROUND/AIMS: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
